Abiomed Inc. (ABMD): Price and Financial Metrics


Abiomed Inc. (ABMD): $380.75

2.96 (+0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ABMD POWR Grades

  • ABMD scores best on the Quality dimension, with a Quality rank ahead of 98.92% of US stocks.
  • The strongest trend for ABMD is in Quality, which has been heading up over the past 26 weeks.
  • ABMD ranks lowest in Value; there it ranks in the 14th percentile.

ABMD Stock Summary

  • Price to trailing twelve month operating cash flow for ABMD is currently 67.9, higher than 94% of US stocks with positive operating cash flow.
  • The ratio of debt to operating expenses for ABIOMED INC is higher than it is for about just 0.51% of US stocks.
  • With a price/sales ratio of 15.87, ABIOMED INC has a higher such ratio than 93.47% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ABIOMED INC, a group of peers worth examining would be HZNP, NTCT, AMSWA, CGNX, and PCTI.
  • ABMD's SEC filings can be seen here. And to visit ABIOMED INC's official web site, go to www.abiomed.com.

ABMD Valuation Summary

  • ABMD's price/sales ratio is 15.9; this is 695% higher than that of the median Healthcare stock.
  • Over the past 243 months, ABMD's price/sales ratio has gone up 12.2.

Below are key valuation metrics over time for ABMD.

Stock Date P/S P/B P/E EV/EBIT
ABMD 2022-12-05 15.9 11.1 63.9 49.5
ABMD 2022-12-02 15.8 11.0 63.8 49.3
ABMD 2022-12-01 15.8 11.1 63.8 49.4
ABMD 2022-11-30 15.9 11.1 63.9 49.4
ABMD 2022-11-29 15.8 11.0 63.8 49.3
ABMD 2022-11-28 15.8 11.0 63.8 49.3

ABMD Growth Metrics

    The year over year price growth rate now stands at -15.8%.
  • The 4 year price growth rate now stands at 87.04%.
  • Its 4 year revenue growth rate is now at 102.83%.
ABMD's revenue has moved up $659,515,000 over the prior 70 months.

The table below shows ABMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,074.096 250.983 266.764
2022-06-30 1,056.317 298.134 217.584
2022-03-31 1,031.753 285.39 136.505
2021-12-31 1,003.148 292.893 133.036
2021-09-30 973.635 281.541 149.152
2021-06-30 935.257 298.178 154.412

ABMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABMD has a Quality Grade of A, ranking ahead of 96.73% of graded US stocks.
  • ABMD's asset turnover comes in at 0.659 -- ranking 58th of 186 Medical Equipment stocks.
  • INGN, KIDS, and ATRC are the stocks whose asset turnover ratios are most correlated with ABMD.

The table below shows ABMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.659 0.819 0.206
2021-06-30 0.655 0.817 0.217
2021-03-31 0.616 0.809 0.303
2020-12-31 0.623 0.809 0.278
2020-09-30 0.643 0.808 0.303
2020-06-30 0.667 0.812 0.248

ABMD Price Target

For more insight on analysts targets of ABMD, see our ABMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $387.33 Average Broker Recommendation 1.65 (Moderate Buy)

ABMD Stock Price Chart Interactive Chart >

Price chart for ABMD

ABMD Price/Volume Stats

Current price $380.75 52-week high $381.99
Prev. close $377.79 52-week low $219.85
Day low $380.25 Volume 1,506,800
Day high $381.80 Avg. volume 485,853
50-day MA $320.96 Dividend yield N/A
200-day MA $287.99 Market Cap 17.17B

Abiomed Inc. (ABMD) Company Bio


Abiomed is a publicly-traded medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices. The company is headquartered in Danvers, Massachusetts with additional offices in WoburnBaltimoreBerlinAachen, and Tokyo. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer and Dr. Chuck Simonton as Chief Medical Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2022, the company had secured five FDA approvals and 1,408 patents with 1,416 pending. For fiscal year 2022, Abiomed reported $1.032 billion in revenue and reported diluted earnings per share was $2.98 for the year. (Source:Wikipedia)


ABMD Latest News Stream


Event/Time News Detail
Loading, please wait...

ABMD Latest Social Stream


Loading social stream, please wait...

View Full ABMD Social Stream

Latest ABMD News From Around the Web

Below are the latest news stories about ABIOMED INC that investors may wish to consider to help them evaluate ABMD as an investment opportunity.

First Patients in the World Treated with Impella RP Flex with SmartAssist

DANVERS, Mass., December 05, 2022--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist.

Yahoo | December 5, 2022

Why Is Abiomed (ABMD) Up 1.2% Since Last Earnings Report?

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 1, 2022

Eleven Stocks Turned $10,000 To $261,421 In 11 Months

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

Yahoo | November 30, 2022

Here's Why You Should Hold on to Abiomed (ABMD) Stock Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Yahoo | November 22, 2022

Here''s How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years

Abiomed (NASDAQ: ABMD ) has outperformed the market over the past 15 years by 18.87% on an annualized basis producing an average annual return of 25.88%. Currently, Abiomed has a market capitalization of $17.04 billion. Buying $1000 In ABMD: If an … Full story available on Benzinga.com

Benzinga | November 21, 2022

Read More 'ABMD' Stories Here

ABMD Price Returns

1-mo 1.80%
3-mo 34.88%
6-mo 52.04%
1-year 21.96%
3-year 111.82%
5-year 98.97%
YTD 6.01%
2021 10.79%
2020 90.05%
2019 -47.52%
2018 73.44%
2017 66.32%

Continue Researching ABMD

Here are a few links from around the web to help you further your research on Abiomed Inc's stock as an investment opportunity:

Abiomed Inc (ABMD) Stock Price | Nasdaq
Abiomed Inc (ABMD) Stock Quote, History and News - Yahoo Finance
Abiomed Inc (ABMD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7644 seconds.